VIVUS Newswire (Page 2)

VIVUS Newswire (Page 2)

Comprehensive Real-Time News Feed for VIVUS. (Page 2)

Results 21 - 40 of 180 in VIVUS

  1. Vivus Inc. (VVUS) Lifted to "Buy" at Zacks Investment ResearchRead the original story w/Photo

    Jul 12, 2016 | Daily Political

    ... Research's target price points to a potential upside of 9.65% from the company's current price. According to Zacks, "VIVUS' key product, Qsymia, targets the highly lucrative obesity market which represents huge commercial potential. Qsymia is the ...

    Comment?

  2. Vivus Inc. (VVUS) Rating Increased to Buy at Zacks Investment ResearchRead the original story w/Photo

    Jul 12, 2016 | AmericanBankingNews.com

    ... Research's target price points to a potential upside of 9.65% from the stock's previous close. According to Zacks, "VIVUS' key product, Qsymia, targets the highly lucrative obesity market which represents huge commercial potential. Qsymia is the ...

    Comment?

  3. Vivus: Qsymia Sales Close Out Q2 With Worst Sales Volume In 2 YearsRead the original story w/Photo

    Jul 11, 2016 | Seeking Alpha

    Vivus investors have tried to find just about anything to be a positive development with the company. It has gotten to the point where the search for "silver linings" has become an art form.

    Comment?

  4. Novo Nordisk - Saxenda Closes Out Q2 On Strong NoteRead the original story w/Photo

    Jul 10, 2016 | Seeking Alpha

    ... said now. 3,900 scripts may not sound impressive given that Belviq from Arena (NASDAQ: ARNA ) sold 8,400, Qsymia from Vivus (NASDAQ: VVUS ) sold 9,100, and Contrave from Orexigen (NASDAQ: OREX ) sold 14,200, but it is actually quite impressive when ...

    Comment?

  5. Vivus Extends Date To Get Back Rights To StendraRead the original story w/Photo

    Jul 5, 2016 | Seeking Alpha

    Vivus announced this week that the company has sought, and obtained, an extension in the turnover date of the erectile dysfunction drug Stendra . Vivus stock traded up on the announcement, but likely not because of anything to do with the extension itself.

    Comment?

  6. Revance Appoints Industry Leader Julian S. Gangolli to its Board of DirectorsRead the original story w/Photo

    Jul 5, 2016 | Freshnews

    ... than 20% a year over a 5-year period. Prior to Allergan, Mr. Gangolli served as Vice President, Sales and Marketing at VIVUS, Inc., where he facilitated the successful transition of the company from a research and development start-up into a niche ...

    Comment?

  7. VIVUS to Extend Return Date of STENDRA Commercial RightsRead the original story w/Photo

    Jun 30, 2016 | Freshnews

    VIVUS, Inc. , a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today announced an extension of the termination date of the license agreement between Auxilium Pharmaceuticals, Inc., a subsidiary of Endo International, plc, and VIVUS for STENDRA U.S. and Canadian commercial rights through August 31, 2016. In December 2015, Auxilium notified VIVUS of its intention to return the U.S. and Canadian commercial rights for STENDRA.

    Comment?

  8. Novo Nordisk - Saxenda Continues To Buck Trends In Anti-ObesityRead the original story w/Photo

    Jun 20, 2016 | Seeking Alpha

    ... and sales that are much lower than what is needed to make a drug candidate in the space viable. Arena (NASDAQ: ARNA ), Vivus (NASDAQ: VVUS ), and Orexigen (NASDAQ: OREX ) are all seeing severe financial challenges due to slow sales. The one company ...

    Comment?

  9. Biotechnology Equities Technical Briefing a " PTC Therapeutics, Biogen, Progenics Pharma, and VIVUSRead the original story

    Jun 14, 2016 | Freshnews

    On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial Average edged 0.74% lower, to finish at 17,732.48; and the S&P 500 closed at 2,079.06, down 0.81%. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. , Biogen Inc. , Progenics Pharmaceuticals Inc. , and VIVUS Inc. .

    Comment?

  10. Vivus - Qsymia Scripts Continue Slow PathRead the original story w/Photo

    Jun 13, 2016 | Seeking Alpha

    Vivus investors are likely used to the Qsymia sales mantra. Flat sales with a bias to the downside.

    Comment?

  11. Vivus: Qsymia Sales Trudge Along - Investors Need Growth, Not FlatnessRead the original story w/Photo

    Jun 6, 2016 | Seeking Alpha

    ... and therefore simply coast along. The problem is so bad that some folks celebrate the most innocuous things. Some Vivus (NASDAQ: VVUS ) investors seem to be in that boat. They are even celebrating the fact that Vivus' Qsymia did not do as bad as ...

    Comment?

  12. VIVUS, Inc. (VVUS) Stock Rating Reaffirmed by JPMorgan Chase & Co.Read the original story w/Photo

    Jun 4, 2016 | AmericanBankingNews.com

    ... number of other brokerages have also weighed in on VVUS. Needham & Company LLC reaffirmed a "hold" rating on shares of VIVUS in a research note on Thursday, March 10th. RBC Capital downgraded VIVUS from an "outperform" rating to a "sector perform" ...

    Comment?

  13. Investor Investigation of VIVUS, Inc. (NASDAQ:VVUS) over Potential Wrongdoing AnnouncedRead the original story w/Photo

    May 26, 2016 | SBWire

    An investigation was announced for current long-term investors in shares of VIVUS, Inc. was announced over potential breaches of fiduciary duties by certain officers and directors at VIVUS, Inc. Investors who purchased shares of VIVUS, Inc. have certain options and should contact the Shareholders Foundation at [email protected] or call +1 779 - 1554. The investigation by a law firm concerns whether certain VIVUS directors breached their fiduciary duties.

    Comment?

  14. Slim pickings in weight-loss drug marketRead the original story w/Photo

    May 23, 2016 | Boston.com

    ... and melt away fat. In 2012, Arena Pharmaceuticals of San Diego launched a new weight-loss drug called Belviq, and Vivus Inc. of San Francisco introduced Qsymia. But physicians proved reluctant to prescribe the new drugs, in part because of a ...

    Comment?

  15. Can Orexigen Take Advantage Of Transition Period?Read the original story w/Photo

    May 17, 2016 | Seeking Alpha

    ... are pacing up by 6.21%. This is a better story than competitors Belviq from Arena (NASDAQ: ARNA ) and Qsymia from Vivus (NASDAQ: VVUS ), but off of the pace that would be needed to impress the street. In order for the company to hit the lowest end ...

    Comment?

  16. Arena Investors: What To Consider As Anti-Obesity Drugs FizzleRead the original story w/Photo

    May 16, 2016 | Seeking Alpha

    ... positive thoughts led Arena (NASDAQ: ARNA ) to partner its drug candidate Belviq with Eisai in a very healthy deal. Vivus (NASDAQ: VVUS ) with its pill Qsymia was in the hunt for a partner as well, but never landed one. Orexigen (NASDAQ: OREX ) was ...

    Comment?

  17. Shareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating...Read the original story w/Photo

    Apr 22, 2016 | PR Newswire

    Shareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating VIVUS, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a securities class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of VIVUS, Inc. . On If you are a shareholder of VIVUS and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: either via email at [email protected] or by telephone at 212-725-1000.

    Comment?

  18. Orexigen: Current Contrave Sales Are Not Meeting Sales ProjectionsRead the original story w/Photo

    May 10, 2016 | Seeking Alpha

    ... hire, train, and deploy its own sales force. The chosen route by Orexigen is very similar to that chosen by competitor Vivus (NASDAQ: VVUS ) with Qsymia. A small dedicated sales force that is highly selective in regions. Look at the past 2 years of ...

    Comment?

  19. Vivus: Sales Flat, Growth NeededRead the original story w/Photo

    May 9, 2016 | Seeking Alpha

    Vivus investors got a dose of the realities of when cost cutting cuts into revenue in Q1 of 2016. The company reported lower overall revenue on a sales decline of about 22,000 scripts.

    Comment?

  20. WallachBeth Capital Lowers VIVUS, Inc. (VVUS) to HoldRead the original story w/Photo

    May 9, 2016 | Daily Political

    A number of other research firms have also recently commented on VVUS. Zacks Investment Research upgraded VIVUS from a sell rating to a hold rating in a research note on Monday, April 11th.

    Comment?